Warning: fopen(/home/virtual/pediatrics/journal/upload/ip_log/ip_log_2024-02.txt) [function.fopen]: failed to open stream: Permission denied in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 82

Warning: fwrite(): supplied argument is not a valid stream resource in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 83
Effect of Recombinant Human Erythropoietin on the Anemia of Premature Infants

Journal of the Korean Pediatric Society 1996;39(5):631-640.
Published online May 15, 1996.
Effect of Recombinant Human Erythropoietin on the Anemia of Premature Infants
Young Ah Lee, Ki Soo Kim, Young Seo Park, Hyung Nam Moon, Chang Yee Hong
Department of Pediatrics, Ulsan University Medical School, and Asan medical Center, Seoul, Korea
미숙아 빈혈에서 Recombinant Human Erythropoietin의 효과
이영아, 김기수, 박영서, 문형남, 홍창의
울산대학교 의과대학 아산재단 서울중앙병원 소아과학교실
Abstract
Purpose
: To determine whether the prophylactic treatment with recombinant human erythropoietin(rHuEPO) for the anemia of prematurity would reduce the need for blood transfusions.
Methods
: We randomly assigned 17 premature infants to therHuEPO group and the control group. For the rHuEPO group (n=9, birth weight=1210¡¾156 g, gestational age=31.7¡¾1.9wk), rHuEPO (400U/kg) was given three times a week for 4 weeks, plus iron (8 mg/kg/day) and vitamin E (25 IU/day). The same amount of vitamin E was only given for the control group (n=8,birth weight=1266¡¾204 g, gestational age=30.0¡¾1.9wk).
Results
: Reticulocyte counts and hematocrit values were higher in the rHuEPO group than the control group at the 4 week of study (10.0¡¾1.5% vs. 5.5¡¾2.1%: p<0.05 and 25.6¡¾4.0% vs. 31.0¡¾1.5%: p<0.05). Also, hemoglobin F were higher in the rHuEPO group than the control group at the 4 week of study (76.2¡¾8.1% vs. 27.2¡¾33.3 %: p<0.05). The rHuEPO treatment group required fewer blood transfusions during the study period (1.25 vs. 0.11: p<0.05). And the complications such as leukopenia, thrombocytosis and infection did not develop during the study period. There was no evidence of irondeficiency state in the both groups.
Conclusion
: The rHuEPO treatment, in combination with iron supplementation, prevented the anemia of prematurity and reduced the need for blood transfusion in the prematureinfants.
Key Words: Recombinant Human Erythropoietin, Anemia of Prematurity


METRICS Graph View
  • 2,146 View
  • 73 Download